Aspira Women's Health 将来の成長

Future 基準チェック /26

Aspira Women's Healthは、15.4%と52.5%でそれぞれ年率15.4%で利益と収益が成長すると予測される一方、EPSはgrowで30.5%年率。

主要情報

15.4%

収益成長率

30.5%

EPS成長率

Medical Equipment 収益成長	17.1%
収益成長率	52.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	18 Nov 2024

今後の成長に関する最新情報

Recent updates

Aspira Women’s Health slips 23% on common stock offering

Aug 22

Aspira Women’s Health GAAP EPS of -$0.07 in-line, revenue of $2.06M misses by $0.34M

Aug 10

Is Aspira Women's Health (NASDAQ:AWH) Using Too Much Debt?

Aug 02

業績と収益の成長予測

NasdaqCM:AWH - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	33	-10	N/A	N/A	3
12/31/2025	20	-15	N/A	N/A	4
12/31/2024	11	-16	N/A	N/A	3
6/30/2024	9	-16	-15	-15	N/A
3/31/2024	9	-15	-15	-15	N/A
12/31/2023	9	-17	-16	-16	N/A
9/30/2023	9	-18	-20	-20	N/A
6/30/2023	9	-21	-24	-24	N/A
3/31/2023	9	-27	-27	-27	N/A
12/31/2022	8	-30	-31	-31	N/A
9/30/2022	8	-34	-32	-32	N/A
6/30/2022	7	-36	-32	-32	N/A
3/31/2022	7	-35	-33	-32	N/A
12/31/2021	7	-32	-28	-27	N/A
9/30/2021	6	-29	-25	-25	N/A
6/30/2021	6	-23	-20	-20	N/A
3/31/2021	5	-20	-17	-16	N/A
12/31/2020	5	-18	-15	-15	N/A
9/30/2020	5	-15	-13	-13	N/A
6/30/2020	5	-15	-13	-13	N/A
3/31/2020	5	-15	-13	-13	N/A
12/31/2019	5	-15	-13	-13	N/A
9/30/2019	4	-15	-13	-12	N/A
6/30/2019	4	-14	-11	-11	N/A
3/31/2019	3	-12	-10	-10	N/A
12/31/2018	3	-11	-9	-9	N/A
9/30/2018	3	-12	-9	-9	N/A
6/30/2018	3	-12	-9	-9	N/A
3/31/2018	3	-12	N/A	-8	N/A
12/31/2017	3	-11	N/A	-8	N/A
9/30/2017	3	-11	N/A	-9	N/A
6/30/2017	3	-11	N/A	-10	N/A
3/31/2017	3	-13	N/A	-11	N/A
12/31/2016	3	-15	N/A	-14	N/A
9/30/2016	2	-17	N/A	-16	N/A
6/30/2016	2	-19	N/A	-17	N/A
3/31/2016	2	-20	N/A	-19	N/A
12/31/2015	2	-19	N/A	-18	N/A
9/30/2015	3	-18	N/A	-18	N/A
6/30/2015	3	-19	N/A	-19	N/A
3/31/2015	3	-19	N/A	-18	N/A
12/31/2014	3	-19	N/A	-17	N/A
9/30/2014	3	-17	N/A	-15	N/A
6/30/2014	3	-14	N/A	-12	N/A
3/31/2014	3	-10	N/A	-10	N/A
12/31/2013	3	-9	N/A	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AWH今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: AWH今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: AWH今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: AWHの収益 ( 52.5% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: AWHの収益 ( 52.5% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AWHの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Aspira Women's Health 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates decrease by 23%, EPS upgraded

Consensus revenue estimates decrease by 23%, EPS upgraded

Price target decreased by 41% to US$3.30

Price target increased by 24% to US$5.60

Consensus revenue estimates decrease by 13%, EPS upgraded

Consensus EPS estimates upgraded to US$2.13 loss, revenue downgraded

Recent updates

Aspira Women's Health Inc. announced delayed 10-Q filing

Aspira Women's Health Inc. to Report Nine Months, 2024 Results on Nov 14, 2024

Aspira Women's Health Inc. Announces Its Selection Receive $10 Million Award from Advanced Research Projects Agency for Health’s Sprint for Women's Health

Aspira Women's Health Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women's Health Inc. Appoints John Kallassy as Interim Chief Financial Officer, Effective August 15, 2024

New major risk - Shareholder dilution

Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $4.45 million.

Aspira Women's Health Inc. to Report Q2, 2024 Results on Aug 12, 2024

Aspira Women’s Health Inc Appoints John Ragard to Its Board of Directors

New major risk - Shareholder dilution

Aspira Women's Health Inc. announced that it has received $1.910249 million in funding

Aspira Women’s Health Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Requirement Pursuant to Nasdaq Listing Rule 5550(b)(2)

Aspira Women's Health Inc. announced that it expects to receive $1.935051 million in funding

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Aspira Women's Health Inc. to Report Q1, 2024 Results on May 15, 2024

Aspira Women's Health Inc. Enhances Its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of Ovawatch

Aspira Women's Health Inc. Announces Minh Merchant Resigns as General Counsel, Chief Compliance Officer, and Corporate Secretary, Effective May 6, 2024

Consensus revenue estimates decrease by 23%, EPS upgraded

Consensus revenue estimates decrease by 23%, EPS upgraded

Aspira Women's Health Inc., Annual General Meeting, May 13, 2024

Price target decreased by 41% to US$3.30

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women's Health Inc. Announces Executive Changes

Aspira Women's Health Inc. to Report Q4, 2023 Results on Mar 28, 2024

Price target increased by 24% to US$5.60

Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $5.50031 million.

Aspira Women's Health Inc. Announces Resignation of Veronica G.H. Jordan from the Board of Directors

Aspira Women's Health Provides Development Update on its Portfolio of Noninvasive Tests for Endometriosis

Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Consensus revenue estimates decrease by 13%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women's Health Inc. to Report Q3, 2023 Results on Nov 13, 2023

High number of new directors

Aspira Women's Health Sees Poster on its MiRNA-Based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research

Aspira Women's Health Establishes A New Clinical Advisory Board

Aspira Women’s Health Regains Nasdaq Compliance

Aspira Women’s Health Announces Executive Changes

Aspira Women’s Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations

Consensus EPS estimates upgraded to US$2.13 loss, revenue downgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women’S Health Inc. Announces Resignation of Ryan Phan as Chief Scientific and Operating Officer, Effective September 15, 2023

Aspira Women's Health Inc. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Share price stability

Aspira Women’s Health Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors, Member of Nominating and Corporate Governance Committee

Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors

High number of new and inexperienced directors

Consensus revenue estimates decrease by 13%

Aspira Women's Health Inc. Announces Chief Financial Officer Changes, Effective June 15, 2023

First quarter 2023 earnings released: US$0.73 loss per share (vs US$1.24 loss in 1Q 2022)

Aspira Women's Health Inc. Appoints Three New Members to Its Board of Directors

Full year 2022 earnings: EPS exceeds analyst expectations

Aspira Women’s Health Inc. Announces Publication of Real-World Data Validating Use of OvaWatch for Management of Adnexal Masses

Aspira Women's Health Inc. Announces Executive Changes

Aspira Women's Health Receives A Written Notice from Nasdaq

Aspira Women's Health Inc. Announces the Commercial Launch of OvaWatch

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women's Health Inc. to Report Q3, 2022 Results on Nov 10, 2022

Aspira Women's Health Inc. Announces Publication of Its Second-Generation Multivariate Index Assay, Overa®, in the Detection of Cancer in Filipino Women

Aspira Women's Health Inc. has completed a Follow-on Equity Offering.

Aspira Women’s Health slips 23% on common stock offering

Consensus forecasts updated

Second quarter 2022 earnings released: US$0.073 loss per share (vs US$0.063 loss in 2Q 2021)

Aspira Women’s Health GAAP EPS of -$0.07 in-line, revenue of $2.06M misses by $0.34M